[go: up one dir, main page]

UY28326A1 - Dispositivo de ruptura de liberacion controlada con un pasaje preformado - Google Patents

Dispositivo de ruptura de liberacion controlada con un pasaje preformado

Info

Publication number
UY28326A1
UY28326A1 UY28326A UY28326A UY28326A1 UY 28326 A1 UY28326 A1 UY 28326A1 UY 28326 A UY28326 A UY 28326A UY 28326 A UY28326 A UY 28326A UY 28326 A1 UY28326 A1 UY 28326A1
Authority
UY
Uruguay
Prior art keywords
release
active agent
passage
preformed
preformed passage
Prior art date
Application number
UY28326A
Other languages
English (en)
Inventor
Joaquina Faqur
Juan A Vergez
Original Assignee
Osmotica Argentina S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28326(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osmotica Argentina S A filed Critical Osmotica Argentina S A
Publication of UY28326A1 publication Critical patent/UY28326A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • External Artificial Organs (AREA)

Abstract

La presente invención provee un dispositivo osmótico simple y mejorado capaz de proveer la liberación controlada de un agente activo contenido en el núcleo al ambiente de uso, primero a través del pasaje preformado y después a través del segundo pasaje formado in situ.Uno o ambos pasajes opcionalmente incrementan su tamano durante el uso del dispositivo osmótico. El pasaje preformado y/o el segundo pasaje incrementa la velocidad de liberación del agente activo, permite la liberación de partículas mayores que contienen agente activo, y/o permite la liberación de agentes activos que son sustancialmente insolubles den el ambiente de uso. En virtud de la formación in situ de la segunda apertura, el dispositivo es capaz de liberar un porcentaje superior de agente activo de lo que liberaría en ausencia de la segunda apertura.
UY28326A 2003-05-22 2004-05-19 Dispositivo de ruptura de liberacion controlada con un pasaje preformado UY28326A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47281903P 2003-05-22 2003-05-22

Publications (1)

Publication Number Publication Date
UY28326A1 true UY28326A1 (es) 2004-06-30

Family

ID=33476979

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28326A UY28326A1 (es) 2003-05-22 2004-05-19 Dispositivo de ruptura de liberacion controlada con un pasaje preformado

Country Status (8)

Country Link
EP (1) EP1629835A2 (es)
KR (2) KR20120105058A (es)
AR (1) AR047204A1 (es)
BR (1) BRPI0410546A (es)
CA (1) CA2526464C (es)
CL (1) CL2004001192A1 (es)
UY (1) UY28326A1 (es)
WO (1) WO2004103349A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409652A (pt) 2003-04-24 2006-04-25 Jagotec Ag tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US20080076743A1 (en) 2006-08-03 2008-03-27 Nitec Pharma Ag Delayed-Release Glucocorticoid treatment of Rheumatoid Disease
EP2099431B1 (en) * 2006-11-28 2013-06-05 Laboratorios Liconsa, S.A. Stabilized solid pharmaceutical composition of candesartan cilexetil
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
AU2007328207A1 (en) 2006-12-05 2008-06-12 Landec Corporation Drug delivery
EP2156833B1 (en) * 2007-05-11 2011-11-30 Santen Pharmaceutical Co., Ltd Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
AU2010250750A1 (en) * 2009-05-22 2011-12-08 Alkem Laboratories Ltd. Pharmaceutical composition of olanzapine and process for their preparation
CN102935074B (zh) * 2011-08-15 2015-04-22 成都康弘药业集团股份有限公司 一种盐酸曲唑酮渗透泵控释片
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
KR101647978B1 (ko) * 2014-03-17 2016-08-24 한국과학기술원 마이크로캡슐을 이용한 삼투압의 직접 측정 방법
EP3258916A1 (en) 2015-02-20 2017-12-27 Osmotica Kereskedelmi ES Szolgaltato KFT Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) * 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4271113A (en) * 1978-04-17 1981-06-02 Alza Corporation Process for forming a passageway in an osmotic device
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
DE20100700U1 (de) * 2001-01-16 2001-03-22 Eugster/Frismag Ag, Romanshorn Kaffeegetränkzubereitungsautomat, insbesondere Espressoautomat
US20030143272A1 (en) * 2001-03-14 2003-07-31 Waterman Kenneth C. Pharmaceutical tablet and process for making thereof
EP1240897B1 (en) * 2001-03-14 2006-06-21 Pfizer Products Inc. Pharmaceutical tablet and process for making thereof
US6809288B2 (en) * 2001-05-23 2004-10-26 Osmotica Corp. Laser drilling system and method

Also Published As

Publication number Publication date
EP1629835A2 (en) 2006-03-01
CL2004001192A1 (es) 2005-03-28
KR20060015286A (ko) 2006-02-16
WO2004103349A3 (es) 2005-03-31
KR20120105058A (ko) 2012-09-24
AR047204A1 (es) 2006-01-11
CA2526464C (en) 2010-06-29
CA2526464A1 (en) 2004-12-02
WO2004103349A2 (es) 2004-12-02
BRPI0410546A (pt) 2006-06-20

Similar Documents

Publication Publication Date Title
UY28326A1 (es) Dispositivo de ruptura de liberacion controlada con un pasaje preformado
UY26546A1 (es) Dispositivo osmótico con un pasaje preformado que aumenta de tamano
AR052545A1 (es) Suspension no acuosa inyectable
MX2018012705A (es) Suministro de agente soluble en surfactante.
CR8814A (es) Composiciones plaguicidas liquidas
ATE536156T1 (de) Vorrichtung zur dauerhaften in-vivo-freisetzung eines aktiven wirkstoffs
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
ATE489048T1 (de) Vorrichtung für kombinierte behandlung
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
EA201190295A1 (ru) Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения
MX384384B (es) Dispositivos de suministro de fármacos con un componente permeable al fármaco y métodos.
AR063571A1 (es) Aparato para el agregado de agentes o ingredientes solubles a un líquido portador, para su administración oral a través de un sorbete
AR082155A1 (es) Formulacion antiseptica y desinfectante que tiene contenido de yodo reducido
IL211085A0 (en) Perfusion solution
PE20090966A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2
AR085290A1 (es) Aparatos y metodos para inyectar en arboles
AR073457A1 (es) Fluidos de dioxido de cloro no citotoxico, composicion oxidante de irritacion reducida
MX2017009893A (es) Encapsulado de agentes activos de alta potencia.
AR076139A1 (es) Metodo para el tratamiento de cultivos con un pesticida encapsulado.
ECSP045063A (es) Formas de dosificacion, dispositivo y procedimientos de tratamiento
DOP2005000248A (es) Agentes citotoxicos que comprendentaxanos nuevos.
MXPA05012319A (es) Suministro de compuestos con celulas sanguineas rehidratadas.
AR029964A1 (es) Agentes herbicidas
ATE413197T1 (de) Zusammensetzungen mit trialkanolamin-alkoxylat- puffer
AR061552A1 (es) Tapones punctales para el suministro de agentes activos

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20160921